The RECOVER open label trial demonstrated positive results for brilaroxazine for schizophrenia.
Laxminarayan Bhat, PhD
Advertisement
Dr Bhat is founder, president, and chief executive officer of
Reviva Pharmaceuticals Holdings Inc.
Articles by Laxminarayan Bhat, PhD
Advertisement
Latest Updated Articles
Open Label Phase 3 Study of Brilaroxazine for Schizophrenia Shows Efficacy, TolerabilityPublished: June 2nd 2025 | Updated:
Advertisement
Advertisement
Trending on Psychiatric Times
1
ADHD Found Connected to Substance Use Disorder, With Sex Prevalence Differences
2
Lithium-Loaded Gold Nanoparticle Nasal Spray to Treat Neuropsychiatric Diseases
3
Sleep as Connective Tissue: Quantifying Team Dynamics in Elite Sports
4
A Moral Injury Update: The PNHP Study and an Imminent Step Toward Peace in the Mideast
5
